• DexCom, Inc. reported past first-quarter 2026 results with sales of US$1.19 billion and net income of US$199.5 million, alongside higher basic and diluted EPS from continuing operations versus a year earlier.
• The company also reaffirmed its 2026 revenue outlook of US$5.16 billion to US$5.25 billion and scheduled a May 14 Investor Day to outline its long-term financial outlook and innovation priorities.
• With stronger quarterly earnings and reiterated full-year revenue guidance, we'll now assess how this past update shapes DexCom's investment narrative.

The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

DexCom Investment Narrative Recap

To own DexCom, I think you need to believe continuous glucose monitoring will stay central to diabetes care and that DexCom can defend its technology and pricing despite competition and reimbursement risks. The latest quarter’s higher sales and net income support that thesis, but do not materially change the key near term catalyst, which is how payer policies and coverage evolve, or the biggest current risk around potential pricing pressure, especially from future CMS actions.

The most relevant update here is DexCom’s reaffirmed 2026 revenue outlook of US$5.16 billion to US$5.25 billion, coming alongside stronger first quarter earnings. Holding guidance steady after this result suggests management still sees the year unfolding broadly as expected, which matters because revenue delivery in 2026 will shape how investors view longer term adoption, margins and the balance between growth opportunities and risks like reimbursement or innovation timing.

Yet investors should be aware that potential pricing shifts, especially around US payers and Medicare coverage, could still...

DexCom's narrative projects $6.6 billion revenue and $1.4 billion earnings by 2029.

Uncover how DexCom's forecasts yield a $86.88 fair value, a 44% upside to its current price.

Exploring Other Perspectives

Before this news, the most pessimistic analysts were assuming revenue of about US$6.4 billion and earnings of roughly US$1.4 billion by 2029, which highlights how cautious some views already were compared with more optimistic expectations around coverage expansion and adoption, and why you may want to compare these different narratives in light of DexCom’s latest numbers.

Explore 3 other fair value estimates on DexCom - why the stock might be worth as much as 44% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your DexCom research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free DexCom research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DexCom's overall financial health at a glance.

No Opportunity In DexCom?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.